NCT02139280View on ClinicalTrials.gov

Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2019

Study Completion Date

September 30, 2020

Conditions
Hematologic Malignancies
Interventions
DRUG

Cyclophosphamide

Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.

Trial Locations (1)

03756

Dartmouth Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT02139280 - Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy | Biotech Hunter | Biotech Hunter